CSL Behring’s Biologics LicenseApplication for the marketing authorization of its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP) has been accepted for review by the U.S.
A recent study found no link between the measles vaccine and autism.
GlaxoSmithKline has developed a new shingles vaccine that is 97 percent effective in adults ages 50 years to 70 years.
A growing number of employers and insurers are limiting how much they’ll pay for certain medical services, according to a recent study.
ADMA Biologics has received positive results on the primary and secondary endpoint evaluations from the Phase III trial for its intravenous immune globulin (IVIG) product RI-002 to treat primary immunodeficiency disease(PI).
Recent research has found a new approach to stimulate the skin immune response to fight various pathogens with an easy-to-use needle-free vaccine.
The Biosimilars 20/20 Conference, at two-day event that will provide an indepth look into the future of the biosimilars market and address challenges of implementation, is scheduled for June3 and 4 at The Hub in Philadelphia, Pa.
The U.S. Food and Drug Administration(FDA) has approved Octapharma’s manufacturing facility in Vienna, Austria, for the production of Octagam 10% (immune globulin intravenous [human] 10% [100mg/mL] liquid preparation).
The “Albumin in Subarachnoid Hemorrhage” (ALISAH) pilot clinical trial, conducted at the Baylor College of Medicine in Houston, assessed the neuroprotective effects of varying dosages of 25% human albumin. Vasospasm, delayed cerebral ischemia (DCI) and cerebral infarction were evaluated in 20 patients who received seven consecutive daily infusions of 0.625 g/kg (Tier 1), 20 who received 1.25 g/kg (Tier 2), and seven who received 1.875 g/kg (Tier 3).
In an established preclinical bleeding model, reversal of coumarin anticoagulation with Kcentra, a four-factor prothrombin complex concentrate (4F-PCC), was shown to be superior to three-factor prothrombin complex concentrates(3F-PCCs), according to findings reported by CSL Behring investigators.
Eight consecutive patients on long-term, hospital-based intravenous immunoglobulin (IVIG) therapy to treat chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) (n=4) and multifocal motor neuropathy (MMN) (n=4) were switched to home-based subcutaneous immunoglobulin (SCIG).
